α2-MACROGLOBULIN AND REDUCED BASEMENT-MEMBRANE DEGRADATION IN DIABETES

Michael Brownlee

doi:10.1016/S0140-6736(76)91614-7

α₂-MACROGLOBULIN AND REDUCED BASEMENT-MEMBRANE DEGRADATION IN DIABETES

Michael Brownlee

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Thickening of the capillary basement membrane is the fundamental morphological alteration of diabetic microangiopathy. Leucocyte neutral proteases can degrade basement membrane in vivo. The activity of a purified neutral protease from granulocytes is inhibited by α₂-macroglobulin. It is suggested that the reported increase in the concentration of α₂-macroglobulin in the blood of diabetic patients inhibits the activity of leucocyte neutral proteases which normally degrade basement membrane. The resultant decreased rate of breakdown would contribute to the increase in basement-membrane material seen in diabetes.

Original language	English (US)
Pages (from-to)	779-780
Number of pages	2
Journal	The Lancet
Volume	307
Issue number	7963
DOIs	https://doi.org/10.1016/S0140-6736(76)91614-7
State	Published - Apr 10 1976
Externally published	Yes

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(76)91614-7

Cite this

@article{ad24ce19cfed41c6a79884e869aab8fd,

title = "α2-MACROGLOBULIN AND REDUCED BASEMENT-MEMBRANE DEGRADATION IN DIABETES",

abstract = "Thickening of the capillary basement membrane is the fundamental morphological alteration of diabetic microangiopathy. Leucocyte neutral proteases can degrade basement membrane in vivo. The activity of a purified neutral protease from granulocytes is inhibited by α2-macroglobulin. It is suggested that the reported increase in the concentration of α2-macroglobulin in the blood of diabetic patients inhibits the activity of leucocyte neutral proteases which normally degrade basement membrane. The resultant decreased rate of breakdown would contribute to the increase in basement-membrane material seen in diabetes.",

author = "Michael Brownlee",

year = "1976",

month = apr,

day = "10",

doi = "10.1016/S0140-6736(76)91614-7",

language = "English (US)",

volume = "307",

pages = "779--780",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "7963",

}

TY - JOUR

T1 - α2-MACROGLOBULIN AND REDUCED BASEMENT-MEMBRANE DEGRADATION IN DIABETES

AU - Brownlee, Michael

PY - 1976/4/10

Y1 - 1976/4/10

N2 - Thickening of the capillary basement membrane is the fundamental morphological alteration of diabetic microangiopathy. Leucocyte neutral proteases can degrade basement membrane in vivo. The activity of a purified neutral protease from granulocytes is inhibited by α2-macroglobulin. It is suggested that the reported increase in the concentration of α2-macroglobulin in the blood of diabetic patients inhibits the activity of leucocyte neutral proteases which normally degrade basement membrane. The resultant decreased rate of breakdown would contribute to the increase in basement-membrane material seen in diabetes.

AB - Thickening of the capillary basement membrane is the fundamental morphological alteration of diabetic microangiopathy. Leucocyte neutral proteases can degrade basement membrane in vivo. The activity of a purified neutral protease from granulocytes is inhibited by α2-macroglobulin. It is suggested that the reported increase in the concentration of α2-macroglobulin in the blood of diabetic patients inhibits the activity of leucocyte neutral proteases which normally degrade basement membrane. The resultant decreased rate of breakdown would contribute to the increase in basement-membrane material seen in diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0017104716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017104716&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(76)91614-7

DO - 10.1016/S0140-6736(76)91614-7

M3 - Article

C2 - 56592

AN - SCOPUS:0017104716

SN - 0140-6736

VL - 307

SP - 779

EP - 780

JO - The Lancet

JF - The Lancet

IS - 7963

ER -